REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo aims to supercharge immune cells against Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial tests whether adding an experimental drug (NKTR-255) to standard CAR-T cell therapy can improve outcomes for adults with large B-cell lymphoma that has returned or not responded to treatment. About 27 participants will receive the combination to see if it i…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:23 UTC
-
New hope for aggressive lymphoma: drug combo aims to unmask cancer cells
Disease control OngoingThis study tests a combination of two drugs (TTI-622 and pembrolizumab) in about 10 adults with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. The drugs work by helping the immune system recognize and attack cancer cells. The goal is to find …
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC